Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
← catalyst calendarNCT06843239 · readout ≤ 285 d
Sponsored by Zura Bio Inc (industry) · ZURA — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
80estimated
Sites
60
Countries
Argentina, Chile, Hungary +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-06 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Sclerosis (SSc)
- Scleroderma
Interventions
- Biological: Tibulizumab — also filed as ZB-106
- Other: Placebo — also filed as ZB-106 placebo
Primary outcomes
what the primary-completion date above is the date OF[Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks
measured Week 24
[Period 2] Safety and tolerability of tibulizumab
measured Week 52
Permalink · ZURA's whole pipeline · Catalyst calendar · Every registered study · What changed